Mymd Pharmaceuticals Inc
NASDAQ:MYMD

  • LAST PRICE
    1.8600
  • TODAY'S CHANGE (%)
    -0.1200 (-6.0606%)
  • Bid / Lots
    1.8200/ 1
  • Ask / Lots
    1.9000/ 2
  • Open / Previous Close
    2.0600 / 1.9800
  • Day Range
    1.8000
    2.0600
  • 52 Week Range
    1.8000
    63.9000
  • Volume
    502,451

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 21, 2024

      Show headlines and story abstract

    • 9:00AM ET on Tuesday May 21, 2024 by Business Wire
      Companies Mentioned: MYMD, PMCB

      PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FDA). PharmaCyte's investment in externally developed technology solidifies its strategy to prudently apply its approximately $65 million (as of March 31, 2024) cash position.

    • 9:00AM ET on Tuesday May 21, 2024 by Business Wire
      Companies Mentioned: MYMD, PMCB

      MyMD Pharmaceuticals, Inc.(R) (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes. An additional $7 million was raised from existing MyMD shareholders participating in the offerings. The closings of the two private placements are each subject to customary closing conditions and are both expected to occur on or around May 22, 2024.

    • 9:00AM ET on Tuesday May 21, 2024 by Dow Jones
      Companies Mentioned: MYMD

      Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front
      BALTIMORE--(BUSINESS WIRE)--May 21, 2024--

Peers Headlines